Background: The aim of this study was to evaluate and compare the cost-effectiveness of varenicline with nicotine replacement therapy (NRT) for smoking cessation in four European countries (Belgium, France, Sweden and the UK). Methods: Markov simulations, using the Benefits of Smoking Cessation on Outcomes (BENESCO) model, were performed. We simulated the incidence of four smoking-related morbidities: lung cancer, chronic obstructive pulmonary disease, coronary heart disease and stroke. The model computes quality-adjusted life-years gained and incremental cost-effectiveness ratios. Incremental cost-utility ratios were calculated, adopting a lifetime perspective. Efficacy data were obtained from a randomized open-label trial: Week 52 continuous abstinence rates were 26.1% for varenicline and 20.3% for NRT. Results: The analyses imply that for countries analysed, smoking cessation using varenicline versus NRT was associated with reduced smoking-related morbidity and mortality. The number of morbidities avoided, per 1000 smokers attempting to quit, ranged from 9.7 in Belgium to 6.5 in the UK. The number of quality-adjusted life-years gained, per 1000 smokers, was 23 (Belgium); 19.5 (France); 29.9 (Sweden); and 23.7 (UK). In all base-case simulations (except France), varenicline dominated (more effective and cost saving) NRT regarding costs per quality-adjusted lifeyear gained; for France the incremental cost-effectiveness ratio was 2803. Conclusion: This costeffectiveness analysis demonstrated that since varenicline treatment was more effective, the result was increased healthcare cost savings in Belgium, Sweden and the UK. Our results suggest that funding varenicline as a smoking cessation aid is justifiable from a healthcare resource allocation perspective.
Introduction

S
moking is one of the major preventable causes of premature death. Smokers face increased risks of developing severe health problems, for instance, lung cancer, respiratory and cardiovascular diseases. Smokers who quit smoking enjoy a reduction in risks of being struck by smoking-related diseases and to suffer premature death. 1 There are a number of licenced pharmacological smoking cessation therapies available to assist smokers in cessation, for instance, nicotine replacement therapy (NRT), and therapies which utilize bupropion or varenicline. The relative efficacy of these therapies has been assessed in systematic reviews and a recent meta-analysis. 2 The highest likelihood for achieving smoking cessation is obtained using a combination of pharmacological aid and dependence counselling. 3 The impact of smoking on society and the consequences on individuals' length of life are considerable. Data from studies performed on European Union (EU) populations suggest that between 1.5% and 6% of total healthcare costs can be attributed to smoking. [4] [5] [6] The indirect costs induced by smoking are also considerable. For instance, smoking attributable life-years lost per year have been estimated, for Swedish conditions, to be about 1000 per 100 000 inhabitants. This estimate is positively related to smoking prevalence and, since the smoking prevalence in Sweden is relatively low, the number of life-years lost per 100 000 inhabitants will be higher than 1000 in most other EU countries. 4 The relation between net costs of achieving smoking cessation and the benefits resulting from smoking cessation depends on the particular institutional and epidemiological setting. In this study, we calculate the cost-effectiveness of smoking cessation therapy using varenicline as compared with smoking cessation using NRT in four European countries.
A number of studies have demonstrated that NRT is costeffective compared with unaided smoking cessation. [7] [8] [9] [10] [11] Recent studies suggest that smoking cessation using varenicline is cost-effective compared with both unaided smoking cessation and smoking cessation interventions using NRT or bupropion. [12] [13] [14] [15] [16] However, previous results comparing varenicline and NRT were obtained using indirect data concerning the relative effectiveness of varenicline and NRT. In this study, we employ published efficacy data from a head-to-head, randomized, open-label study of varenicline and NRT (patches) in smoking cessation. 17 We report on the number of morbidity-events avoided and the cost-effectiveness of using varenicline compared with NRT (patches) in Belgium, France, Sweden and the UK, using the Benefits of Smoking Cessation on Outcomes (BENESCO) Markov simulation model. 15 
Methods
The BENESCO simulation model BENESCO is a recently developed simulation model that predicts smoking-related morbidity and mortality using published health-related risks faced by smokers. 15 The model rests on the same fundamental structure and functioning as the HECOS (Health Economic Consequences of Smoking) simulation model, which was prepared for and reviewed by the World Health Organization European Partnership Project to Reduce Tobacco Dependence. 18 The model adopts a national healthcare perspective including intervention costs and morbidity-related healthcare costs. The BENESCO model follows the life cycle of a cohort of current smokers after making a single attempt to quit smoking (it is assumed that 25% of all smokers make an attempt to quit smoking at the beginning of the simulation). The model simultaneously predicts the subsequent effects on morbidity and mortality associated with each smoking cessation intervention considered. The incremental effect of a particular therapy compared with another is estimated as the difference between morbidity and mortality in the two interventions.
The model distinguishes between men and women in three age groups: (i) 18-34; (ii) 35-64; and (iii) 65 and older as well between (a) those without morbidity; (b) those with morbidity; and (c) those who have died. With respect to morbidity/mortality risk, the model also distinguishes between (1) current smoker; (2) recent quitter-stopped smoking between 1 and 5 years ago; and (3) long-term quitterabstinent for at least six years. As regards the risk of relapse, the model distinguishes between (1) those attempting to quit (in the first year); (2) recent quitters-stopped smoking between one and five years ago; (3) medium-term quittersstopped smoking between six and 10 years ago; and (4) longterm quitters-stopped smoking >10 years ago. The risk of relapse, during the first simulated year, is equal to the 1-year continuous abstinence rate obtained in the head-to-head study mentioned above; 17 the risks of relapse for recent quitters, medium-term quitters and long-term quitters, respectively, are collected from published studies regarding smoking relapse. 19, 20 Four smoking-related diseases are simulated in the model: chronic obstructive pulmonary disease (COPD); coronary heart disease (CHD); lung cancer; and stroke. According to present epidemiological knowledge, these diseases cover most of the health problems associated with smoking. 4, 18 The risk of developing one of these smoking-related diseases, or to die, that current and former smokers face, is utilized in the calculations of expected number of cases of morbidity and mortality in the simulated population. More specifically, the risk of developing smoking-related disease, or die, was calculated for each smoking state.
The Supplementary data contain a detailed illustration of the functioning of the model. More detailed descriptions of the BENESCO simulation model have been published in previous cost-effectiveness studies. [12] [13] [14] [15] [16] 21 Input data
The following country-specific input data were utilized in the simulation model: (i) prevalence, incidence and mortality rates for each of the diseases considered; (ii) total-population mortality rates; (iii) average annual morbidity-specific healthcare costs; and (iv) smoking prevalence. The simulation model comprises the following default data, which were used for all countries: (i) relative morbidity and mortality risks of smokers and former smokers; (ii) morbidity-specific quality-adjusted life-year (QALY) weights; and (iii) relapse rates.
The country-specific input data are presented in the supplementary data. Data used to compute empirical measures of the input data for a specific country were not, in all cases, collected in that particular country. For example, Dutch data were utilized for some of the input variables as a close substitute of data collected for a Belgian population (for data sources, see references in table footnotes). A number of recent publications include descriptions of the default data incorporated in the BENESCO simulation model. 15 All costs and benefits were discounted at 3.5%.
Efficacy
Efficacy rates used in the simulations were imputed from a recent head-to-head study of the efficacy of varenicline compared with NRT in smoking cessation therapy. 17 The study included 747 participants aged 18-75 years and was performed at sites in Belgium, France, The Netherlands, the UK and the US. Continuous abstinence rate (CAR) at Week 52 was 26.1% for the varenicline alternative and 20.3% for the NRT alternative (nicotine patches) [odds ratio (OR) = 1.40; 95% confidence interval (CI): 0.99-1.99; P-value = 0.056].
Sensitivity analyses
The extent to which the cost-effectiveness of varenicline compared with NRT in smoking cessation interventions is sensitive to the levels of respective data components employed in the simulations is reflected by the parallel and countryspecific results. Base-case cost-effectiveness results are reported both for a typical smoking cessation intervention in each country when the individual initiates healthcare contact to receive advice, and for smoking cessation interventions that utilize a minimum of healthcare resources. Additional univariate sensitivity analyses were performed regarding (i) morbidity-specific QALY weights; (ii) intervention cost; (iii) healthcare costs; (iv) discount rates; and (v) efficacy. Results from the stochastic sensitivity analyses are provided in the supplementary data.
Results
Base-case analysis
The results are presented for two base-case scenarios: (i) smoking cessation interventions are consistent with suggested local established clinical practice with regard to healthcare and drug utilization; and (ii) for each country, smoking cessation interventions included the minimum of healthcare contacts allowed by law (for varenicline, at least one physician visit; for NRT no healthcare contacts are required). Results for these two base-case scenarios are presented in Tables 1 and 2 . All analyses correspond to the country-specific input values provided in the supplementary data and reflect a lifetime perspective. Results are reported separately for each country, and for (i) incremental costs; (ii) healthcare costs averted; (iii) QALYs gained; and (iv) the incremental cost per QALY gained.
For all four countries, smoking cessation using varenicline instead of NRT was associated with reductions in smokingrelated morbidities. The largest reductions occurred for COPD in Sweden-6.3 avoided cases per 1000 smokers (that receive Cost-effectiveness of varenicline smoking cessation treatment). The corresponding number of avoided cases in the UK was 3.7; the number of avoided cases in France and Sweden, respectively, falls between those for Belgium and the UK. For lung cancer, CHD and stroke, all countries avoid about the same number of cases per 1000 smokers (Table 1) . Life-years and QALYs gained, respectively, varied between 15.5 (France) and 28.7 (Sweden), and between 19.5 (France) and 29.9 (Sweden). The avoided healthcare costs, resulting from use of varenicline instead of NRT, varied between approximately 100 000 Euros (Belgium) and 199 000 Euros (UK) ( Table 2 ). In Case 1 (a typical smoking cessation intervention for each country), using varenicline instead of NRT was cost saving in all countries except France; the cost-effectiveness ratio in the French case was about 2800 Euros per QALY gained. In Case 2 (a minimum of healthcare resources deployed in smoking cessation interventions), the costeffectiveness ratios varied between about 50 Euros (UK) and about 2800 Euros (France).
Sensitivity results
The sensitivity analyses showed that intervention costs and the relative efficacy rate are the two most important determinants of cost-effectiveness. Table 3 presents results from the univariate sensitivity analyses. The highest cost-effectiveness ratio was obtained by assuming an efficacy rate for varenicline of 22.1% (lowered by 4% points from 26.1%). In this case, the simulation for France produced a cost-effectiveness ratio of about 26 000 Euros per QALY. The French case deviated considerably from the corresponding figures for Belgium, Sweden and the UK.
Discussion
In this study, we performed analyses of the cost-effectiveness of varenicline compared with NRT in smoking cessation interventions across four European countries-Belgium, France, the UK and Sweden. These countries differ regarding The fundamental functioning of the simulation model is to exploit relative disease-specific mortality risks associated with smokers and former smokers 1 in order to simulate lifetime differences in morbidity and mortality between smokers that make a quit-smoking attempt using varenicline and smokers making an attempt using NRT.
Current guidelines for treating tobacco dependence acknowledge the use of three first-line drugs, vareniclne, NRT and bupropion. 22 Clonidine and nortriptyline are considered as the second-line medications. However, the objective of this article was to identify the most cost-effective treatment, and it does not recommend which therapy should be used as first line or second line treatment.
Qualitatively, and for all countries, the results show that smoking cessation using varenicline instead of NRT avoids additional cases of morbidity and reduces smoking-related mortality. Quantitatively, the results differ somewhat between countries. The largest number of avoided cases of morbidity (per 1000 smokers) occurs in Belgium (9.7), and the smallest in the UK (6.5). The largest number of life-years gained occurs in Sweden (28.7); the smallest occurs in France (15.5). By and large, the simulations show that the number of avoided cases of morbidity is about the same in all countries, but that the number of life-years gained differs significantly. Plausible explanations for this are differences in healthcare efficiency or healthcare-related resource allocation. For example, for every Swedish smoker who quit smoking, the expected gain in life-years was twice as much compared with a French smoker who quits. This suggests that the French healthcare sector is more efficient in reducing smoking-related mortality.
In addition to life-years gained from smoking cessation, the costs related to smoking cessation intervention and smokingrelated morbidities are considered in this case. Thus, differences between the countries regarding cost-effectiveness may arise because of healthcare efficiency differences (or allocative differences) and/or because of differing costs in the healthcare sectors.
The cost-effectiveness results indicate that using varenicline in smoking cessation interventions is cost-effective compared with use of NRT, even though the gains vary somewhat between the different countries considered. This finding corroborates previous evidence that smoking cessation using varenicline is cost saving and more efficient than use of NRT. For example, treating German 23 and Dutch 12 smokers with varenicline rather than NRT has been found to be cost saving.
According to Bolin et al., 21 the willingness to pay for a QALY varies considerably from study to study. However, the smallest value they reported is 13 000 Euros, which is well above any of the cost-effectiveness ratios reported in our base-case scenarios 1 and 2. In fact, the only cost-effectiveness ratios that we obtained above 13 000 were for France and involve considerably lower efficacy rates. This implies that even if some of the input values used in our simulations provide imperfect measures of the true values, using varenicline instead of NRT in smoking cessation therapy is likely to be a cost-effective allocation of scarce resources.
The sensitivity analyses suggest that apart from the relative efficacy rate, the most plausible causes of differing cost-effectiveness ratios are differing intervention-and morbidity-related healthcare costs. Thus, assuming that the efficacy rates do not vary between countries, the differences between estimated cost-effectiveness are likely to be induced by variations in these costs. Intervention costs differ (i) because unit costs concerning healthcare goods and time used in the intervention differ and (ii) because the amount of resources used in smoking cessation interventions differs. Likewise, avoided morbidity-related healthcare costs also differ because unit costs and resource utilization vary between the countries.
The results in this study do not incorporate the indirect effects on production (reduced sickness absenteeism in the labour market) of the respective countries caused by lower rates of smoking-related morbidity. Similarly, the effects of reduced mortality on the values of production and consumption have not been taken into account. 24, 25 This will influence the calculated cost-effectiveness ratios. First, by excluding the morbidity effects, we obtain a conservative measure of the cost-effectiveness ratio. This is because the losses from smoking-related work absenteeism are quite large-smoking results in 10 additional days of work absenteeism per year. 26 Bolin et al. 21 discuss the magnitude of this for Sweden. Second, the effects of reduced mortality are two-fold: reduced mortality among those in the workforce implies increased production, which would improve the cost-effectiveness of varenicline since the average value of the production performed by these individuals outweighs their consumption. 21 In contrast, individuals who are not active in the workforce may consume more than they produce. However, there is also householdrelated production, which may be more evenly distributed over the age groups, implying that reduced mortality among the retirees will also increase the benefits from smoking cessation. The morbidity effects are likely to outweigh the mortality effects, and therefore incorporation of these indirect effects would have strengthened our conclusion that using varenicline instead of NRT in smoking cessation therapy is justifiable from a societal perspective.
In conclusion, our analyses-using country-specific data on smoking prevalence and disease-specific morbidity and mortality, and costs for both morbidity-specific healthcare and smoking cessation interventions-suggest that varenicline in smoking cessation therapy is cost-effective compared with NRT in various real-life situations. Moreover, the sensitivity analyses suggest that this conclusion holds even though the country-specific data employed in the simulations differ somewhat between the countries with respect to year of collection.
Supplementary data
Supplementary data are available at EURPUB online.
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Key points
Recent studies have suggested that smoking cessation with varenicline is cost-effective compared with NRT. These studies, however, utilized indirect data concerning the relative effectiveness of these two interventions. Our simulations employ recent data from a headto-head, randomized, open-label trial comparing varenicline and NRT in smoking cessation. Using country-specific data regarding smoking prevalence, disease-specific morbidity and mortality and costs, our results suggest that varenicline is costeffective compared with NRT in various real-life situations. These results suggest that funding varenicline as a smoking cessation aid may be justifiable from a healthcare resource allocation perspective.
